Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma
10.3760/cma.j.issn.0254-5098.2021.08.009
- VernacularTitle:早期结外鼻型NK/T细胞淋巴瘤放化疗疗效与不良反应分析
- Author:
Weixin LIU
1
;
Dan ZHAO
;
Zhou HUANG
;
Xiaolong XU
;
Shaowen XIAO
;
Baomin ZHENG
;
Ningjing LIN
;
Yuqin SONG
;
Weihu WANG
;
Yan SUN
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所放射治疗科 恶性肿瘤发病机制及转化研究教育部重点实验室 100142
- Keywords:
Extranodal nasal-type NK/T-cell lymphoma;
Radiotherapy;
Outcome;
Toxicity
- From:
Chinese Journal of Radiological Medicine and Protection
2021;41(8):615-621
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy and toxicity of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL).Methods:Retrospective review was conducted for 174 patients with pathological proved early stage ENKTCL who were treated in the Department of Radiation Oncology, Peking University Cancer Hospital & Institute. The Kaplan-Meier survival analysis was adopted to calculate the local-regional control (LRC), overall survival (OS), and progression free survival (PFS), and the Log-rank test COX regression model were applied to univariate and multivariate analyses.Results:The patients in this study included 102 and 72 patients diagnosed with Ann Arbor stage-Ⅰ and stage-Ⅱ, respectively. Among them, two patients received radiotherapy alone and 172 patients were treated with combined chemoradiotherapy. The overall response rate of all the patients was 94.2%, with a complete response (CR) rate of 87.9% (153). Furthermore, the rates of 5-year OS, PFS, and LRC were 87.3%, 83.1%, and 91.9%, respectively. The most common toxicities during the chemotherapy and radiotherapy included myelosuppression and oral mucositis, with grade ≥ 3 myelosuppression and grade ≥ 3 oral mucositis accounting for 62.1% and 10.9% of all patients, respectively. As shown by multivariate analysis, the adverse prognostic factors for OS included age > 60, B symptoms, and stage Ⅱ, while the adverse prognostic factors for PFS included age > 60 and stage Ⅱ. Meanwhile, the PFS rate was significantly improved by increasing the radiation dose (≥ 50 Gy vs.<50 Gy), and the 5-year PFS rates of the two groups were 83.5% and 76.5%, respectively [hazard ratio ( HR) 0.374; 95% CI, 0.169-0.826; P=0.015]. Conclusions:A good therapeutic effect can be achieved for early stage NK/T-cell lymphoma and the toxicities after combined chemoradiotherapy can be tolerated.
